ReviewClinical kidney journal2026
Managing hyponatremia: fast or slow? Why, when, how, and controversies.
Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyponatremia is the most common electrolyte disorder encountered in clinical practice. Its management is challenging because treatment must balance the risk of cerebral edema in acute hyponatremia against the risk of osmotic demyelination syndrome (ODS) from overly rapid correction of chronic hyponatremia. Recent observational studies have questioned current correction limits, prompting renewed debate regarding optimal management. This narrative review presents a physiology-based approach to the evaluation and treatment of hyponatremia. Acute hyponatremia may cause life-threatening cerebral edema because cerebral adaptation is incomplete, whereas chronic hyponatremia is characterized by the loss of intracellular electrolytes and organic osmolytes that limit brain swelling but increase vulnerability to osmotic injury during correction. Because the duration of hyponatremia is often uncertain, management should be guided primarily by neurological manifestations rather than duration alone. We propose a systematic treatment approach based on neurological severity, the duration of hyponatremia when definitively known, and the patient's risk of neurological injury, balancing the immediate danger of cerebral edema against the risk of ODS. We critically review the evidence underlying current correction limits and recent observational studies reporting that ODS is uncommon, inconsistently associated with overly rapid correction, and that slower correction has been associated with higher mortality. We conclude that, until higher-quality evidence becomes available, conservative correction limits for management of chronic hyponatremia remain appropriate, with correction not exceeding 10 mmol/l in 24 h (18 mmol/l in 48 h) in average-risk patients, targeting a rise of 4-8 mmol/l/day, and 8 mmol/l in 24 h in patients at high risk for ODS, targeting a rise of 4-6 mmol/l/day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.